Given the breadth of potential immunoinhibitory pathways available in the tumor microenvironment in addition to PD-1 and CTLA-4, the next critical questions to tackle include the following: (1) Which immunoinhibitory pathway blockade regimens should be combined to enhance and sustain antitumor responses and thus improve cancer patient outcomes? This evidence concerns the gene CTLA4 and neoplasm.